MGMT Status

Total

(n = 20)

Methylated (n = 12)

Unmethylated (n = 8)

Nil response

1 (8.3%)

1 (12.5%)

2 (10%)

Yes

11 (91.7%)

7 (87.5%)

18 (90%)

TMZ with RT ® adj TMZ * 1 year

5 (41.7%)

2 (25%)

7 (35%)

Irinotecan+ bevacizumab

1 (8.3%)

5 (62.5%)

6 (30%)

Bevacizumab alone

2 (16.7%)

0 (0%)

2 (10%)

Lost follow up

2 (16.7%)

0 (0%)

2 (10%)

SRS

1 (8.3%)

0 (0%)

1 (5%)